Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance

doi:10.3969/j.issn.1673-8640.2013.04.012

Abstract

Abstract: Objective　To investigate the change and clinical significance of serum high mobility group protein box-1 (HMGB1) in patients with gastric cancer. Methods　The serum levels of HMGB1 were determined by enzyme-linked immunosorbent assay (ELISA) in 101 patients with gastric cancer，31 patients with benign gastric diseases and 40 healthy controls. Simultaneously，serum carcinoembryonic antigen(CEA) was determined by electrochemiluminescence (ECL). The results were expressed as median (range). Results　The levels of serum HMGB1 and CEA in patients with gastric cancer were 15.58（3.05-125.63）ng/mL and 11.75（0.85-850.23）ng/mL. The levels of serum HMGB1 and CEA in patients with benign gastric diseases were 4.46（2.61-12.06）ng/mL and 2.75（0.52-11.23）ng/mL. The levels of serum HMGB1 and CEA in healthy controls were 3.24（2.50-5.38）ng/mL and 1.23（0.45- 4.56）ng/mL. The levels of serum HMGB1 and CEA in patients with gastric cancer were significantly higher than those in patients with benign gastric diseases and healthy controls ( P＜0.01）. The levels of serum HMGB1 were significantly associated with tumor size，gastric wall invasion, TNM stage and lymph node metastasis（P＜0.05）. Compared to the traditional tumor marker CEA, the diagnostic sensitivity and specificity of serum HMGB1 were 72.2% and 74.6% for the diagnosis of early gastric cancer. Conclusions　HMGB1 plays a role in the tumorigenesis and development of gastric cancer. The determination of HMGB1 in serum of patients with gastric cancer is helpful for improving early diagnosis, monitoring and predicting the prognosis in gastric cancer.

Key words: High mobility group protein box-1, Tumor marker, Enzyme-linked immunosorbent assay, Gastric cancer

XIAO Jinhua，ZHU Huayan，WANG Yaping，PAN Yuhong，HUANG Xuan. Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance[J]. , 2013, 28(4): 301-304.

References

[1]Hotta K，Oyama T，Akamatsu T，et al. A comparison of outcomes of endoscopic submucosal dissection(ESD) for early gastric neoplasms between high-volume and low-volume centers: multi-center retrospective questionnaire study conducted by the Nagano ESD study group[J]. Intern Med，2010,49(4):253-259.
[2]Tang D，Kang R，Zeh H J 3rd，et al. High-mobility group box 1 and cancer[J]. Biochim Biophys Acta,2010,1799(1-2):131-140.
[3]Yamada S，Yakabe K，Ishii J，et al. New high mobility group box 1 assay system[J]. Clin Chim Acta，2006，372(1-2): 173-178.
[4]Yang H，Wang H，Czura CJ，et al. The cytokine activity of HMGB1 [J]. J Leukoc Biol，2005，78(1): 1-8.
[5]Moriwaka Y，Luo Y，Ohmori H，et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer[J]. Pathobiology，2010,77(1):17-23.
[6]Rauvala H，Rouhiainen A. RAGE as a receptor of HMGB1(amphoterin): roles in health and disease[J]. Curr Mol Med，2007，7(8):725-734.
[7]Bao G，Qiao Q，Zhao H，et al. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas[J]. World J Surg Oncol，2010，8:52.
[8]Chung HW，Lee SG，Kim H，et al. Serum high mobility group box-1(HMGB1) is closely associated with the clinical and pathologic features of gastric cancer[J]. J Transl Med，2009,7:38.
[9]Campana L，Bosurgi L，Rovere-Querini P. HMGB1:a two-headed signal regulating tumor progression and immunity[J]. Curr Opin Immunol，2008,20(5):518-523.
[10]Volz HC，Kaya Z，Katus HA，et al. The role of HMGB1/RAGE in inflammatory cardiomyopathy [J]. Semin Thromb Hemost,2010,36(2):185-194.
[11] Volp K, Brezniceanu ML, B?sser S，et al. Increased expression of high mobility group box 1(HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas [J]. Gut，2006,55(2):234-242.

[1]	LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329.
[2]	XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356.
[3]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[4]	WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881.
[5]	NIE Tian, RAN Zihan, JIN Lei. Research progress on the relationship between interleukin gene polymorphisms and gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 882-886.
[6]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance [J]. Laboratory Medicine, 2022, 37(5): 409-412.
[7]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[8]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[9]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[10]	MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46.
[11]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.
[12]	MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59.
[13]	XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7.
[14]	HANG Chen, HUANG Biao, PENG Haixia, WEI Xin, XU Weihong, SHENG Huiming, LI Ningli. Role of TRFIA for detecting pepsinogen in screening ulcer gastric cancer [J]. Laboratory Medicine, 2020, 35(7): 721-725.
[15]	HU Yan, SHEN Ge, LI Qiong, ZENG Ziyan, , YANG Gang, LI Ping, CHEN Yufeng, ZHANG Zhen, XIE Xiaobing. Roles of 2 SARS-CoV-2 antibody assays in the diagnosis of corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(12): 1294-1297.